ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$26.15 (+113.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
ANAPTYSBIO, INC grew revenue 92.9% to $237.61M over the twelve months to Jun 30, 2026. Operating income rose 229.5% to $312.93M, moving the operating margin from 77.1% to 131.7%. Free cash flow was $19.61M.
Revenue
$237.61M
+92.9% vs. a year earlier
Operating income
$312.93M
+229.5% vs. a year earlier
Free cash flow
$19.61M
FY2025
EPS, diluted
-$0.44
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.28B
- P/E ratio
- –
- Price to sales
- 9.59
- Price to book
- 215.20
- Dividend yield
- –
- Free cash flow yield
- 0.86%
Fundamentals
- Revenue
- $237.61M
- Net income
- $195.72M
- EPS, diluted
- -$0.44
- Free cash flow
- $19.61M
- Book value per share
- $0.23
- Diluted shares
- 46M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$237.61M+92.9% YoY
Operating income
$312.93M+229.5% YoY
Net income
$195.72M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months